Triflusal | Interleukin Related interleukin-related.com

Product Name :
Triflusal

Search keywords :
Triflusal

drugId :
null

Target Vo:
Unidentified

Target Vo Short Name :
Unidentified

Moa_Name:
Platelet aggregation inhibitors

First Approval Country :
Spain

First Approval Date Filter:
1981

Origin Company_Name :
Uriach

Active Company_Name :
Furen Pharmaceutical Group Co Ltd

Active Indication_Name:
Thromboembolism

In Active Indication_Name:
Insulin Resistance

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Phospholipase C gamma 1 Rabbit mAb Data Sheet
Alpha-ENaC Antibody manufacturer
KDM1A Antibody (YA718): KDM1A Antibody (YA718) is a non-conjugated and Mouse origined monoclonal antibody about 93 kDa, targeting to KDM1A (1B2). It can be used for WB assays with tag free, in the background of Human, Mouse, Monkey.

Author: Interleukin Related

Related Posts